New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2014
08:54 EDTEPZM, CELGEpizyme payment from Celgene suggests data positive, says JMP Securities
JMP Securities believes that the $25M proof of concept payment that Epizyme (EPZM) received from Celgene (CELG) suggests that the fourth dose cohort in the Phase I dose escalation study of Epizyme's EPZ-5676 yielded positive results. The firm reiterates a $40 price target and Outperform rating on Epizyme.
News For EPZM;CELG From The Last 14 Days
Check below for free stories on EPZM;CELG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
14:45 EDTEPZMNew Enterprise Associates reports 15.4% stake in Epizyme
Subscribe for More Information
August 20, 2014
08:02 EDTCELGBristol-Myers, Celgene enter collaboration agreement for OPDIVO, ABRAXANE
Subscribe for More Information
August 19, 2014
09:38 EDTCELGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD TSLA CELG VLO VZ FB HD
07:33 EDTCELGCelgene announces publication of REVLIMID combination results
Celgene announced that results of a study evaluating the combination of REVLIMID with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone in untreated diffuse large b-cell lymphoma were published online ahead of print in the Journal of Clinical Oncology. In a phase II, open label, single arm study, 64 patients with newly diagnosed, untreated, stage II-IV CD20 positive DLBCL received 25 mg of lenalidomide on days 1-10 with standard dose R-CHOP every 21 days for six cycles. All patients received pegfilgrastim on day two of each cycle and aspirin prophylaxis throughout. The primary endpoint was event-free survival with secondary endpoints of progression free survival and overall survival. A one-stage binomial design was used to assess the efficacy and tolerability of REVLIMID with R-CHOP. Of the 64 patients enrolled, 60 were eligible for response evaluation. In these patients, the overall response rate was 98% with 80% achieving a complete response. The 24-month EFS, which was identical to PFS, and OS rates were 59% and 78%, respectively. The company said, "This study demonstrated that the addition of lenalidomide to conventional R-CHOP resulted in similar PFS rates and OS rates between sub-types. This is intriguing as patients with the non-GCB phenotype have traditionally experienced poorer outcomes. The results of this study support further evaluation of this regimen in this sub-type of DLBCL.
August 15, 2014
10:12 EDTEPZMEpizyme management to meet with Leerink
Subscribe for More Information
August 13, 2014
07:33 EDTEPZMEpizyme reports Q2 EPS (40c), consensus (50c)
Reports Q2 revenue $9.49M, consensus $7.58M. Expects to end 2014 with more than $170M in cash and cash equivalents, it believes will fund the company until at least mid-2016, prior to including any potential future milestone payments.
August 12, 2014
17:12 EDTEPZMEpizyme reports MTD not reached in 3 dose cohorts from EPZ-6438 Phase 1 trial
Subscribe for More Information
15:56 EDTEPZMEpizyme rises 5.3% to $35.93
A late day move higher in shares of Epizyme came in concert with the posting of a presentation dated August 12, entitled "EZH2 Inhibitor EPZ-6438 (E7438) in Non-Hodgkin Lymphoma: Pre-Clinical Models and Early Clinical Observations," to the company's website. Reference Link
15:23 EDTEPZMNotable companies reporting before tomorrow's open
Subscribe for More Information
August 11, 2014
06:54 EDTEPZMAmerican Society of Hematology to hold a meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use